Primary trastuzumab-resistance after (neo)adjuvant trastuzumab-containing treatment for HER2-positive breast cancer patients in real-world practice

2020 ◽  
Author(s):  
Xuelian Chen ◽  
Jiayu Wang ◽  
Ying Fan ◽  
Yang Luo ◽  
Pin Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Breast Cancer Patients ◽  
Trastuzumab Resistance ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab

Breast Cancer ◽  
2013 ◽  
Vol 22 (3) ◽  
pp. 292-299 ◽  
Author(s):  
Junichi Kurebayashi ◽  
Naoki Kanomata ◽  
Tetsumasa Yamashita ◽  
Toshiro Shimo ◽  
Akiko Mizutoh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
E. C. Inwald ◽  
O. Ortmann ◽  
F. Zeman ◽  
M. Koller ◽  
F. Hofstädter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Large Population ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positive breast cancer patients. Data from the clinical cancer registry Regensburg (Germany) were analyzed. The present study investigated 6,991 female patients with primary invasive breast cancer. In premenopausal HER2-positive patients a considerable increase of trastuzumab therapy was observed from 58.1% in 2006 to 90.9% in 2011, whereas in postmenopausal patients trastuzumab was rather used on a constant rate of 49.1%. Best overall survival (OS) was found in HER2/steroid hormone receptor-positive patients receiving guideline concordant treatment with trastuzumab plus chemotherapy (CHT) plus antihormone therapy (AHT) with a 7-year OS rate of 96% compared to the non-trastuzumab group with a 7-year OS rate of 92%. In multivariable analysis, HER2-positive patients treated with CHT or AHT who did not get trastuzumab, had a worse 7-year OS (65%,P=0.006versus 79%,P=0.017) than the control groups. This population-based study demonstrated that guideline concordant use of adjuvant trastuzumab improves OS for HER2-positive breast cancer patients treated in routine clinical care.

Sign in / Sign up

Export Citation Format

Share Document